NCT04640623 2026-03-13SunRISe-1Janssen Research & Development, LLCPhase 2 Active not recruiting220 enrolled 1 FDA
NCT02365597 2026-01-30An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerJanssen Research & Development, LLCPhase 2 Active not recruiting239 enrolled 32 charts 1 FDA
NCT01835158 2021-02-11Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerNational Cancer Institute (NCI)Phase 2 Completed157 enrolled 10 charts 1 FDA